Fact-checked by Grok 2 weeks ago

Entourage effect

The entourage effect is a hypothesis in cannabis pharmacology proposing that the therapeutic benefits of Cannabis sativa are potentiated through synergistic interactions among its diverse phytochemicals, including cannabinoids, terpenes, and flavonoids, rather than the action of isolated compounds alone.^[1] This phenomenon suggests that full-spectrum cannabis extracts can enhance efficacy and reduce side effects in conditions such as pain, epilepsy, and inflammation, by modulating bioavailability, receptor binding, and downstream signaling pathways.^[2] First described in the context of endogenous cannabinoids, the concept has evolved to explain the polypharmacy of plant-derived cannabis, emphasizing its biochemical complexity over single-molecule therapies.^[3] The term "entourage effect" was originally coined in 1998 by Shimon Ben-Shabat and colleagues, who observed that inactive endogenous lipids enhanced the anti-inflammatory activity of the endocannabinoid 2-arachidonoylglycerol (2-AG) in preclinical models.^[3] This idea was later extended to Cannabis sativa by Raphael Mechoulam and others in the late 1990s, recognizing parallels between the plant's phytocannabinoids and the body's endocannabinoid system.^[4] The concept gained prominence in 2011 through Ethan Russo's review, which highlighted potential synergies between cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD) with terpenoids, framing it as a key rationale for using whole-plant preparations in medicinal cannabis.^[5] Central to the entourage effect are the major classes of cannabis compounds, which interact to produce therapeutic effects. Proposed mechanisms include pharmacokinetic enhancements and pharmacodynamic synergies. These interactions are thought to underpin variations in cannabis effects, influencing selective breeding for therapeutic profiles.^[2] Supporting evidence includes preclinical and clinical studies where full-spectrum extracts often outperform isolates; for instance, a randomized trial found THC:CBD oromucosal spray (nabiximols) superior to THC alone for cancer pain relief.^[6] In epilepsy, meta-analyses indicate CBD-rich extracts achieve seizure reduction at lower doses (6.0 mg/kg/day) with fewer adverse events than purified CBD (25.3 mg/kg/day).^[7] Animal models demonstrate enhanced responses from combined formulations compared to isolates. However, human trials remain limited, highlighting the need for standardized research.^[4] Despite its appeal, the entourage effect faces criticism for insufficient empirical validation, with contradictory results and concerns over marketing misuse. Ongoing debates emphasize rigorous terminology and further research, as clinical applications evolve.^[8]

Introduction

Definition

The entourage effect refers to the synergistic interaction among multiple bioactive compounds in the cannabis plant, including cannabinoids, terpenes, and flavonoids, which collectively produce enhanced therapeutic, pharmacological, or psychoactive outcomes that surpass the effects of isolated compounds alone. This phenomenon suggests that the full spectrum of cannabis constituents modulates each other's activities through complementary mechanisms, such as receptor binding, enzymatic inhibition, or improved bioavailability, leading to more balanced and potent results in areas like pain relief, anti-inflammation, and neuroprotection.^[9] The concept emphasizes the importance of whole-plant extracts over purified isolates in harnessing cannabis's potential benefits. The term "entourage effect" was first coined in 1998 by researchers Raphael Mechoulam and Shimon Ben-Shabat in a study examining how inactive endogenous fatty acid glycerol esters enhance the activity of the endocannabinoid 2-arachidonoylglycerol.^[10] Although the original paper focused on endogenous compounds in the body's endocannabinoid system, the idea was later extended to phytocannabinoids and other plant-derived molecules in cannabis, highlighting similar modulatory interactions.^[11] Illustrative examples of this synergy include the combination of tetrahydrocannabinol (THC) and cannabidiol (CBD), where CBD can mitigate THC's psychoactive side effects, such as anxiety and cognitive impairment, while amplifying their shared anti-inflammatory properties through enhanced receptor modulation. Similarly, the terpene myrcene may facilitate greater absorption of cannabinoids across the blood-brain barrier, thereby intensifying their overall therapeutic impact in full-spectrum preparations.^[12]

Historical Development

The isolation of Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, by Raphael Mechoulam and Yechiel Gaoni in 1964 represented a foundational advancement in understanding the plant's phytochemistry. Published in the Journal of the American Chemical Society, this work elucidated THC's structure through chromatographic isolation from hashish and partial synthesis, shifting scientific focus from folklore to empirical analysis of cannabis constituents and setting the stage for hypotheses about interactive effects among them.^[13] The concept of the entourage effect was formally coined in 1998 by Shimon Ben-Shabat, Raphael Mechoulam, and colleagues in a seminal paper in the European Journal of Pharmacology. The study demonstrated that inactive endogenous fatty acid glycerol esters, such as oleoyl glycerol and linoleoyl glycerol, potentiated the immunosuppressive and hypothermic effects of the endocannabinoid 2-arachidonoylglycerol (2-AG) in mouse models, without binding to cannabinoid receptors themselves. This proposed a synergistic "entourage" mechanism where non-active metabolites enhance cannabinoid activity, inspiring its extension to phytocannabinoids in whole-plant extracts.^[10] During the 2000s, research on full-spectrum cannabis extracts gained momentum, with studies illustrating how combinations of cannabinoids outperformed isolates in preclinical models of pain and inflammation. This period built on the entourage framework by emphasizing the role of minor compounds in modulating therapeutic outcomes. A pivotal 2011 review by Ethan B. Russo in the British Journal of Pharmacology further popularized the hypothesis in medical contexts, synthesizing evidence for phytocannabinoid-terpenoid synergies and advocating for strain-specific formulations to optimize clinical efficacy.^[14] The passage of the 2018 U.S. Farm Bill, which legalized hemp production and removed it from Schedule I classification, catalyzed a surge in research funding and material availability, enabling more rigorous exploration of entourage interactions. By the mid-2020s, this had facilitated clinical trials on full-spectrum formulations; for instance, a 2024 randomized controlled trial by researchers at Johns Hopkins University and the University of Colorado provided human evidence that d-limonene, when combined with THC, mitigates THC-induced anxiety, supporting entourage-based therapeutic strategies.^[15]

Key Compounds

Cannabinoids

Cannabis sativa produces over 100 distinct phytocannabinoids, lipid-based compounds that structurally resemble endocannabinoids and primarily interact with the endocannabinoid system (ECS) by binding to cannabinoid receptors CB1 and CB2, as well as other targets like TRP channels and serotonin receptors.^[16] These phytocannabinoids are biosynthesized from precursors such as geranyl pyrophosphate and olivetolic acid, forming a diverse class of molecules that modulate physiological processes including pain, inflammation, and mood.^[16] Among the major phytocannabinoids, Δ⁹-tetrahydrocannabinol (THC) is the primary psychoactive compound, exerting its effects mainly through agonism at CB1 receptors in the central nervous system, which are densely expressed in brain regions involved in cognition and reward.^[16] THC's chemical structure is represented by the formula C_{21}H_{30}O_2, featuring a dibenzopyran ring system that enables its lipophilic binding to the ECS.^[16] In isolation, high doses of THC can induce anxiety and paranoia due to excessive CB1 activation, disrupting emotional processing.^[17] Cannabidiol (CBD), sharing the same molecular formula C_{21}H_{30}O_2 but with a distinct open-ring structure, is non-psychoactive and influences inflammation primarily via partial agonism at CB2 receptors on immune cells and agonism at serotonin 5-HT1A receptors, promoting anxiolytic and anti-inflammatory outcomes without intoxicating effects.^[16] CBD can antagonize THC's anxiogenic properties when co-administered, halving subjective anxiety ratings in human studies by modulating THC's impact on emotional circuits.^[17] Additionally, CBD inhibits THC metabolism through competitive inhibition of cytochrome P450 enzymes (e.g., CYP3A4 and CYP2C19), resulting in elevated and prolonged THC plasma levels that alter its pharmacokinetic profile.^[4] Cannabigerol (CBG), with formula C_{21}H_{32}O_2, acts as the acidic precursor (CBGA) to THC, CBD, and other cannabinoids in the plant's biosynthetic pathway and demonstrates antibacterial activity against methicillin-resistant Staphylococcus aureus by disrupting bacterial membranes and inhibiting growth.^[18] CBG binds weakly as a partial agonist to both CB1 and CB2 receptors, contributing to anti-inflammatory and neuroprotective effects within the ECS.^[16] Cannabinol (CBN), formula C_{21}H_{26}O_2, arises from the oxidative degradation of THC upon exposure to light, heat, or air, and exhibits mild psychoactivity with prominent sedative properties through low-affinity agonism at CB1 and CB2 receptors, potentially enhancing sleep onset in preclinical models.^[19]

Terpenes

Terpenes are aromatic hydrocarbons derived from isoprene units, forming a diverse class of volatile compounds in plants, including Cannabis sativa. They are classified by carbon chain length, with monoterpenes consisting of two isoprene units (C10H16, such as limonene and pinene) and sesquiterpenes comprising three units (C15H24, such as myrcene). More than 200 terpenes and terpenoids have been identified in cannabis, primarily responsible for the strain-specific aromas like earthy, citrusy, or pine-like scents that distinguish varieties.^[1] In cannabis, terpenes are biosynthesized in glandular trichomes, the resin-producing structures on flowers and leaves, via two complementary pathways: the cytosolic mevalonate (MVA) pathway, which generates isopentenyl pyrophosphate (IPP) precursors from acetyl-CoA, and the plastidial 2C-methyl-D-erythritol-4-phosphate (MEP) pathway, which also yields IPP and dimethylallyl pyrophosphate (DMAPP). These precursors are then enzymatically converted by terpene synthases into specific terpenes, with concentrations in dried flowers typically ranging from 0.5% to 2% by weight, though this varies significantly across strains due to genetic and environmental factors.^[20]^[21] Key terpenes contribute distinct pharmacological profiles relevant to the entourage effect. Myrcene, the most abundant sesquiterpene in many strains, is linked to sedative effects, often producing a "couch-lock" sensation at levels above 0.5%, and may enhance cannabinoid absorption by increasing cell membrane permeability. Limonene, a prominent monoterpene, exhibits mood-elevating and anti-anxiety properties, potentially mitigating THC-induced stress. Pinene, another monoterpene, demonstrates anti-inflammatory effects and acts as a bronchodilator, aiding respiratory function. These terpenes, while non-psychoactive on their own, may synergize with cannabinoids to modulate therapeutic outcomes.^[21]

Flavonoids and Other Compounds

Flavonoids represent a class of polyphenolic compounds abundant in Cannabis sativa, with more than 30 distinct types identified, predominantly consisting of flavones and flavonols.^[22] These include common examples such as apigenin and quercetin, which contribute to the plant's pigmentation and structural integrity.^[23] Unique to cannabis are the prenylated flavones known as cannflavins A and B, which demonstrate potent anti-inflammatory effects by inhibiting prostaglandin E2 production in human rheumatoid synovial cells at levels approximately 30 times more effective than aspirin.^[24] Beyond flavonoids, other minor metabolites play supportive roles in the entourage effect. Alkaloids occur in low concentrations within cannabis and exhibit potential neuroprotective properties, such as spermidine-type alkaloids that act as inhibitors of butyrylcholinesterase, an enzyme implicated in neurodegenerative processes.^[25] Hydrocarbons, numbering around 50 identified compounds, along with simple sugars, facilitate the solubility and stability of lipophilic cannabinoids within the plant matrix, potentially aiding their extraction and absorption.^[26] Fatty acids, including oleic acid, contribute by forming glycerol esters that enhance cannabinoid signaling, thereby modulating receptor sensitivity in the endocannabinoid system. In terms of synergy, flavonoids bolster the entourage effect through their antioxidant capabilities, which protect cannabinoids from oxidative degradation during processing and storage.^[23] Additionally, these compounds can improve cannabinoid bioavailability by modulating gut permeability and inhibiting efflux transporters, facilitating greater intestinal absorption.^[27]

Mechanisms of Interaction

Synergistic Effects

The entourage effect encompasses various types of interactions among cannabis compounds, including additive effects where the combined impact equals the sum of individual contributions, potentiation where one compound amplifies the potency of another beyond simple addition, and antagonism where one compound mitigates the undesirable effects of another.^[4] These interactions contribute to the overall therapeutic profile of cannabis extracts, distinguishing them from isolated compounds. For instance, cannabidiol (CBD) can antagonize certain psychoactive side effects of tetrahydrocannabinol (THC), such as paranoia, by reducing the intensity of THC-elicited symptoms in experimental settings.^[28]^[4] In therapeutic contexts, these synergistic effects may enhance outcomes in areas like pain management and anti-nausea activity. For pain relief, the combination of THC and the terpene myrcene may contribute to potentiation through myrcene's muscle-relaxant and sedative properties, potentially amplifying THC's action on pain pathways, as suggested in preclinical models.^[29]^[4]^[30] Similarly, in chemotherapy patients, full-spectrum cannabis products may exhibit anti-nausea effects through potential additive and potentiating interactions, where THC's primary anti-emetic properties are modulated by CBD to potentially improve symptom control, though clinical evidence remains limited.^[4] Pharmacokinetic synergy further supports the entourage effect by altering the absorption, distribution, metabolism, and excretion (ADME) of cannabis compounds, leading to prolonged and enhanced efficacy. Cannabinoids like CBD can inhibit drug-metabolizing enzymes such as hepatic cytochrome P450 (CYP450), slowing THC breakdown and extending its therapeutic window, while terpenes may influence bioavailability through increased membrane permeability.^[4]^[31] This modulation ensures more sustained plasma levels of active compounds, optimizing overall pharmacological performance without increasing individual doses. Recent 2024 reviews confirm potential synergies in these mechanisms but emphasize the need for more standardized clinical studies.^[1]

Pharmacological Interactions

The entourage effect arises from intricate pharmacological interactions among cannabis compounds at the molecular level, particularly involving receptor modulation, enzyme inhibition, and activation of non-cannabinoid pathways. Terpenes, such as β-caryophyllene, can act as direct agonists at CB2 receptors, while others like myrcene and limonene may enhance cannabinoid binding through allosteric modulation of CB1 and CB2 receptors, thereby amplifying the signaling efficacy of THC and other cannabinoids.^[32]^[33] Flavonoids contribute similarly by inhibiting fatty acid amide hydrolase (FAAH), the enzyme responsible for endocannabinoid degradation; for instance, kaempferol, a common flavonoid, competitively inhibits FAAH with a Ki value of 5 μM, elevating levels of anandamide and 2-arachidonoylglycerol to potentiate endocannabinoid tone.^[34]^[35] Enzyme interactions further underpin these synergies, with CBD serving as a potent inhibitor of cytochrome P450 enzymes CYP2D6 and CYP3A4, which are key in THC metabolism; this inhibition prolongs THC's half-life and enhances its bioavailability when co-administered.^[31]^[36] Myrcene, a prevalent terpene, increases cell membrane permeability, including across the blood-brain barrier, facilitating faster absorption and onset of cannabinoids like THC by promoting their transcellular transport.^[12]^[37] Beyond cannabinoid receptors, non-cannabinoid pathways are engaged, broadening the entourage effect's scope. Monoterpenes such as α-pinene may modulate transient receptor potential vanilloid 1 (TRPV1) channels, contributing to analgesic effects by desensitizing these nociceptive sensors, as suggested in preclinical models of inflammation and pain.^[38] Limonene may influence mood and anxiety regulation through modulation of serotonin (5-HT) neuronal function, complementing cannabinoid-mediated effects in full-spectrum extracts.^[39]^[40] These interactions collectively enhance the therapeutic profile without relying solely on direct cannabinoid receptor activation.

Applications in Cannabis Strains

Indica vs. Sativa Hypotheses

Traditional classifications of cannabis strains distinguish between Cannabis indica and Cannabis sativa based on morphology, geographic origin, and perceived psychoactive effects. Indica strains, originating from regions like Afghanistan and India, are typically short, bushy plants with broad leaves, associated with sedative, body-focused effects such as relaxation and sleepiness, often attributed to higher levels of myrcene.^[41] In contrast, sativa strains, from equatorial areas like Thailand and Mexico, are taller with narrower leaves and linked to energizing, cerebral effects like alertness and euphoria, commonly due to elevated tetrahydrocannabinol (THC) and terpenes such as limonene.^[42] These distinctions have guided consumer choices, with indica preferred for evening use and pain relief, while sativa is favored for daytime productivity.^[42] The entourage effect hypothesis posits that the unique chemical profiles of indica and sativa strains produce distinct synergies among cannabinoids, terpenes, and other compounds, explaining their differential effects beyond THC alone. In indica strains, the combination of high myrcene with THC is thought to amplify relaxation through enhanced sedative properties, where myrcene contributes to muscle relaxation and "couch-lock" sensations, potentially potentiating cannabinoid absorption and calming the central nervous system.^[43] For sativa strains, the interplay of limonene with high THC levels may promote focus and mood elevation by increasing dopamine and serotonin activity in brain regions associated with motivation and reward.^[43] These interactions illustrate how strain-specific compound ratios could modulate neurotransmitter pathways, creating tailored therapeutic outcomes via the entourage effect.^[44] However, modern research highlights challenges to these traditional categories due to widespread genetic hybridization in cultivated cannabis, which has blurred morphological and chemical distinctions between indica and sativa. By the 2020s, extensive crossbreeding has rendered the binary classification unreliable for predicting effects, as many commercial strains exhibit mixed profiles.^[45] Consequently, experts advocate for a chemovar approach, classifying strains based on their full cannabinoid and terpene compositions rather than indica/sativa labels, to better align with entourage effect dynamics and improve consistency in medical applications.^[45]

Criticisms of Strain Differentiation

A 2015 genetic analysis of 340 marijuana varieties demonstrated only a moderate correlation (r² = 0.36) between reported Cannabis indica and C. sativa ancestry and actual genetic structure, largely due to extensive interbreeding that has blurred traditional distinctions. This admixture undermines the reliability of indica/sativa labels for predicting morphology, such as plant height or leaf shape, or pharmacological effects, as modern strains exhibit high genetic variability regardless of labeling.^[46] The entourage effect, reliant on synergistic interactions among cannabinoids, terpenes, and other compounds, shows greater variation across individual plants within the same labeled strain than between indica and sativa categories, influenced by factors like cultivation environment and growing conditions. A 2023 study of genetically identical plants grown indoors versus outdoors revealed significant differences in terpene diversity—such as higher sesquiterpene levels (e.g., β-caryophyllene) in outdoor samples—and cannabinoid degradation, highlighting how these profile shifts could alter therapeutic outcomes more than strain designations.^[47] Critics argue that indica/sativa labeling prioritizes industry marketing over scientific precision, as a 2021 genomic survey of over 100 commercial samples found these terms correlated weakly with terpene and cannabinoid content (explaining less than 20% of chemical variation) but strongly with seed bank origins, indicating commercial branding drives categorization rather than biology. This disconnect has prompted calls for regulatory reform, with a 2024 analysis recommending abandonment of binary strain labels in favor of standardized cannabinoid-terpene profiling to ensure accurate product testing and consumer information. However, as of 2025, many regulatory frameworks continue to require indica/sativa/hybrid designations on product labels.^[48]^[49]^[50]

Scientific Evidence and Research

Supporting Studies

One of the earliest experimental demonstrations of the entourage effect involved in vitro and in vivo assessments of endocannabinoid interactions. In a 1998 study, Ben-Shabat and colleagues, including Raphael Mechoulam, showed that inactive endogenous fatty acid glycerol esters enhanced the binding and activity of the endocannabinoid 2-arachidonoylglycerol to cannabinoid receptors, potentiating its pharmacological effects without direct receptor binding by the esters themselves.^[10] This "entourage" mechanism illustrated how non-active analogs could amplify cannabinoid signaling in neuronal tissues. Building on such findings, a 2011 review by Ethan Russo examined terpene-cannabinoid synergies, highlighting how terpenoids like myrcene and limonene modulate THC and CBD effects through interactions with neurotransmitter systems, such as serotonin and GABA receptors, to produce enhanced anti-inflammatory and analgesic outcomes in preclinical models.^[14] Clinical evidence supporting the entourage effect has emerged from trials comparing cannabis extracts to isolates. A 2011 phase 3 randomized, double-blind, placebo-controlled study by Novotna et al. evaluated Sativex, a THC:CBD oromucosal spray, in 241 randomized patients with multiple sclerosis and refractory spasticity; nabiximols showed a significant reduction in mean spasticity NRS (change -0.19 vs. +0.64 for placebo, p=0.0002), with 74% of nabiximols-treated 30% responders maintaining response after 12 weeks (vs. 51% placebo).^[51] Similarly, a 2018 observational data meta-analysis by Millar et al. analyzed data from multiple studies (330 patients on CBD-rich extracts achieving 37% responder rate at average 6 mg/kg/day; 223 on purified CBD at 25.3 mg/kg/day with 42% responders), suggesting potential for lower-dose efficacy with full-spectrum though not statistically significant (p=0.52). Recent clinical evidence, such as a 2024 study, demonstrated that combining THC with the terpene limonene significantly reduced anxiety more effectively than THC alone in human participants.^[52] Animal models have further substantiated synergistic antitumor effects. In a 2018 preclinical study by Blasco-Benito et al., using athymic nude mice with HER2+ breast cancer xenografts, a botanical drug preparation (BDP) containing THC plus minor cannabinoids and terpenes showed greater antitumor effects than pure THC, reducing tumor growth more potently through enhanced receptor modulation and apoptosis. These results underscore the role of entourage interactions in amplifying therapeutic potency beyond isolated compounds.

Criticisms and Limitations

The scientific evidence supporting the entourage effect remains limited by the predominance of small-scale, preclinical studies and a notable lack of large-scale randomized controlled trials (RCTs). A 2017 analysis highlighted that, despite growing interest, no double-blind clinical trials had been conducted to rigorously test interactions among cannabis terpenes and cannabinoids beyond THC, with much of the field relying on anecdotal reports rather than controlled experimentation.^[53] Additionally, many investigations are industry-funded, which raises concerns about potential bias in study design and interpretation, as evidenced by reviews noting the scarcity of independent, large-cohort research.^[54] Reproducibility is further hampered by the inherent variability in cannabis plant chemistry, including differences in chemovar profiles, extraction methods, and environmental factors, which complicate consistent outcomes across studies.^[4] Critics argue that claims about the entourage effect often exceed the available data, with insufficient proof for broad synergistic interactions among all proposed compounds. For instance, some observed enhancements in therapeutic effects may stem from pharmacokinetic factors, such as improved bioavailability or altered metabolism of cannabinoids (e.g., THC bioavailability ranging from 4-20%), rather than true entourage synergies.^[4] A 2023 scoping review emphasized this distinction, suggesting that the concept is frequently overhyped as a marketing tool in the cannabis industry, where full-spectrum products are promoted without robust validation of their superiority over isolated compounds.^[4] This discrepancy between promotional narratives and empirical evidence underscores the risk of misleading consumers about unverified benefits. Addressing these limitations requires advancements in research methodologies, including the development of standardized cannabis extracts to minimize variability in compound profiles and dosing.^[4] Genomic profiling of cannabis strains, which has identified key genetic markers influencing terpene and cannabinoid production (e.g., regions on chromosomes 5 and 6 linked to specific terpenes like myrcene), could enable more precise breeding for reproducible entourage-like effects.^[48] Furthermore, ethical concerns persist regarding medical claims for entourage-based therapies, as cannabis-derived products lack FDA approval for such indications as of 2025, leading to warnings against unsubstantiated therapeutic promotions that could harm patients.^[55]^[56] High-quality RCTs and regulatory oversight are essential to bridge these gaps and ensure evidence-based applications.

References

[1]
The Entourage Effect in Cannabis Medicinal Products
The entourage effect is often attributed to beneficial synergistic effects, with discussions typically avoiding potential antagonistic or additive adverse ...
[2]
The Case for the Entourage Effect and Conventional Breeding of ...
Jan 9, 2019 · The case for Cannabis synergy via the “entourage effect” is currently sufficiently strong as to suggest that one molecule is unlikely to match the therapeutic ...
[3]
https://doi.org/10.1016/S0014-2999(98)00392-6
[4]
Decoding the Postulated Entourage Effect of Medicinal Cannabis
Aug 21, 2023 · Advocates suggest that the 'entourage effect' is the reason many patients experience an overall better effect from full-spectrum products.
[5]
https://doi.org/10.1111/j.1476-5381.2011.01238.x
[6]
The Case for the Entourage Effect and Conventional Breeding of ...
Jan 8, 2019 · The case for Cannabis synergy via the “entourage effect” is currently sufficiently strong as to suggest that one molecule is unlikely to match the therapeutic ...
[7]
An entourage effect: inactive endogenous fatty acid glycerol esters ...
This effect ('entourage effect') may represent a novel route for molecular regulation of endogenous cannabinoid activity. Publication types. Research Support, ...
[8]
Does the “Entourage Effect” in Cannabinoids Exist? A Narrative ...
The Entourage Effect Hypothesis. The term entourage effect was first proposed by the Israeli researchers Raphael Mechoulam and Simon Ben-Shabat in 1998, who ...
[9]
Myrcene—What Are the Potential Health Benefits of This Flavouring ...
β-Myrcene may also have a role in assisting cannabinoids to be absorbed across the blood-brain barrier, increasing transport into the brain and enhancing ...
[10]
Isolation, Structure, and Partial Synthesis of an Active Constituent of ...
Article April 1, 1964. Isolation, Structure, and Partial Synthesis of ... Raphael Mechoulam. Novel Synthesis of C-Methylated Phytocannabinoids Bearing ...
[11]
Taming THC: potential cannabis synergy and phytocannabinoid ...
This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, ...
[12]
New Study Shows Clinical Evidence of the Entourage Effect as D ...
Apr 10, 2024 · New Study Shows Clinical Evidence of the Entourage Effect as D-Limonene Mitigates Anxiety in Combination with THC. April 10, 2024. Researchers ...
[13]
Major Phytocannabinoids and Their Related Compounds
Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, ...
[14]
Does Cannabidiol Protect Against Adverse Psychological Effects of ...
Oct 16, 2013 · When CBD and THC were administered together, the anxiogenic effect of THC was halved. This was an important indication that the anxiety-inducing ...
[15]
Cannabigerol (CBG): A Comprehensive Review of Its Molecular ...
Nov 20, 2024 · Current studies revealed that CBG has potential therapeutic effects on neuroprotection, inflammation, antibacterials, metabolic syndrome, pain ...
[16]
Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and ...
CBN is not synthesized in the cannabis plant, but is derived during the degradation of Δ9-THC. Even under ideal storage conditions, exposure to UV light and ...
[17]
Terpenes/Terpenoids in Cannabis: Are They Important? - PMC - NIH
Chemotypes high in myrcene will result in a “couch lock” effect (if a sample has over 0.5% myrcene), while chemotypes with low levels of myrcene (<0.5% myrcene) ...
[18]
Terpene synthases from Cannabis sativa | PLOS One
Mar 29, 2017 · Terpene biosynthesis in plants involves two pathways to produce the general 5-carbon isoprenoid diphosphate precursors of all terpenes, the ...
[19]
Chemistry and Biological Activities of Cannflavins of the Cannabis ...
Oct 11, 2023 · More than 30 flavonoids were isolated from the plant including the characteristic flavonoids called cannflavins, which are prenylated or geranylated flavones.
[20]
Flavonoids in Cannabis sativa: Biosynthesis, Bioactivities, and ... - NIH
Feb 18, 2021 · More than 20 flavonoids, mostly flavones and flavonols, have been identified in C. sativa, including cannflavins, which are prenylated and ...
[21]
Flavonoids in Cannabis sativa: Biosynthesis, Bioactivities, and ...
Feb 18, 2021 · This mini-review examines recent advances in the biosynthesis and bioactivities of cannflavins, which are prenylated (C5) and geranylated (C10) flavones that ...Introduction · Biosynthesis of Cannflavins in... · Bioactivities of Cannflavins
[22]
Novel Butyrylcholinesterase Inhibitor Alkaloids from Cannabis sativa ...
Cannabis sativa synthesizes spermidine-type alkaloids, whose potential biological activities have been little studied. This study aimed to isolate bioactive ...
[23]
Chemical Composition of Commercial Cannabis - ACS Publications
Various studies have reported more than 550 different compounds in cannabis. These include >140 cannabinoids, 120 terpenes, 50 hydrocarbons, 46 phenolic or ...
[24]
Cannabidiol and Contributions of Major Hemp Phytocompounds to ...
This review summarizes the complex interaction of CBD with its main targets, possible modulatory effects by other phyto- and endocannabinoids
[25]
Cannabidiol inhibits THC-elicited paranoid symptoms and ... - PubMed
Oct 5, 2012 · In agreement, post-THC paranoia, as rated with the State Social Paranoia Scale (SSPS), was less in the CBD group compared with the placebo group ...Missing: entourage | Show results with:entourage
[26]
Taming THC: potential cannabis synergy and phytocannabinoid ...
Jul 12, 2011 · This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, ...
[27]
A closer look at cannabimimetic terpenes, polyphenols, and flavonoids
Altogether, cannabinoids, polyphenols, flavonoids, terpenoids, and essential oils extend the therapeutic benefits of each compound, known as the entourage ...
[28]
https://pubmed.ncbi.nlm.nih.gov/23042808/
[29]
FAAH Modulators from Natural Sources: A Collection of New ...
Apr 5, 2025 · Phytocannabinoids, flavonoids, and flavolignans have been shown to efficiently inhibit FAAH. The structural diversity and bioactivity of these ...
[30]
Inhibition of fatty acid amide hydrolase by kaempferol and ... - NIH
Among the commonly occurring flavonoids, kaempferol was the most potent, inhibiting FAAH in a competitive manner with a Ki value of 5 μM. Among flavonoids with ...Missing: cannabis | Show results with:cannabis
[31]
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism
Jun 28, 2021 · Most of the cannabinoids inhibited CYP2C19, whereas CYP2D6, CYP3A4, and CYP2B6 were either not affected or only partially inhibited by the ...
[32]
Contemplating cannabis? The complex relationship between ... - NIH
Several studies indicate that CBD inhibits CYP450 enzymes, typically due to competitive inhibition. Specifically, in vitro and in vivo studies have demonstrated ...
[33]
https://doi.org/10.1016/j.bcp.2023.115548
[34]
https://pmc.ncbi.nlm.nih.gov/articles/PMC11989041/
[35]
https://pmc.ncbi.nlm.nih.gov/articles/PMC2538700/
[36]
Cannabis, a complex plant: different compounds and different effects ...
Indica-dominant strains are short plants with broad, dark green leaves and have higher cannabidiol content than the sativa plants in which THC content is higher ...
[37]
A Cross-Sectional Survey of Cannabis Users - PMC - NIH
Indica and sativa cannabis allegedly elicit different effects due to variations in classes of compounds found in cannabis (e.g., cannabinoids, terpenes, and ...
[38]
The Cannabis sativa Versus Cannabis indica Debate: An Interview ...
CCR: Sativa is often described as being uplifting and energetic, whereas indica as being relaxing and calming. Can you speculate on what could be the basis for ...
[39]
The “Entourage Effect”: Terpenes Coupled with Cannabinoids for ...
The “entourage effect” is the suggested positive contribution derived from the addition of terpenes to cannabinoids.
[40]
Classification of Cannabis Strains Based on their Chemical ...
Aug 13, 2024 · Introduction: Cannabis cultivars were usually categorized based on their genetic profile as sativa, indica, or hybrid types.Missing: 2020s | Show results with:2020s
[41]
The Genetic Structure of Marijuana and Hemp | PLOS One
We find a moderate correlation between the genetic structure of marijuana strains and their reported C. sativa and C. indica ancestry and show that marijuana ...Missing: labels don't
[42]
Comparison of the Cannabinoid and Terpene Profiles in ...
We compared the terpene and cannabinoid profiles using gas/liquid chromatography and mass spectrometry for commercial cannabis from genetically identical plants ...
[43]
Cannabis labelling is associated with genetic variation in terpene ...
Oct 14, 2021 · Analysis of over 100 Cannabis samples quantified for terpene and cannabinoid content and genotyped for over 100,000 single nucleotide ...<|control11|><|separator|>
[44]
Classification of Cannabis Strains Based on their Chemical ...
Aug 18, 2024 · Differentiating cannabis strains based on their chemical profiles is important because different chemovars can have different effects and ...
[45]
A randomized, double-blind, placebo-controlled, parallel ... - PubMed
We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.
[46]
Some of the Parts: Is Marijuana's "Entourage Effect" Scientifically ...
Apr 20, 2017 · Still, there is no hard evidence that the entourage effect is real. Double-blind clinical trials, the gold standard for research studies in ...<|control11|><|separator|>
[47]
Between Science and Big Business: Tapping Mary Jane's ...
While there is evidence that combined administration of cannabinoids can result in an “entourage effect”, the few reported small-scale studies that were ...
[48]
Warning Letters for Cannabis-Derived Products - FDA
Sep 3, 2025 · This page lists FDA warning letters for firms marketing cannabis-derived products, including CBD and delta-8 THC, to protect the public.Missing: ethical | Show results with:ethical
[49]
https://www.liebertpub.com/doi/full/10.1089/can.2024.0127